Blood Group Genotyping for Sickle Cell and Thalassaemi

NHS England, Leeds · awarded 13 May 2025 · delivered in England

£141k Award value £140,671
1 Supplier Recorded as a small or medium-sized business
31 Mar 2026 Runs until from 12 May 2025

Who

BuyerNHS England, Leeds Leeds
Supplier NHS BLOOD AND TRANSPLANT (NHSBT)
Categoryservices
ClassificationBlood analysis services CPV 85111810
Notice published3 September 2025

What it is for

The main output of this programme is for blood group genotyping to become embedded into routine practice. Primary objective (benefit) of doing so is to ensure patients with rare blood disorders have a minimise risk of adverse reactions through access to blood group genotyping.

Read the original award notice on Contracts Finder →

Other contracts from this buyer

4 awards on file, worth £3.5m.

Everything NHS England, Leeds has awarded →

Other contracts won by this supplier

3 awards on file, worth £210k.

Everything NHS BLOOD AND TRANSPLANT (NHSBT) has won →